Over the past decade, advances in nano-enabled healthcare reveal that further advances on this scale are a potential game-changer. Whether talking about nano-scale diagnostics, pharmaceuticals, or therapeutics, the importance of considering the ethical, social, and regulatory aspects of this burgeoning area of technological miniaturization is vital in minimizing the adverse impacts on the environment and public health. The most significant concern involves a lack of a standardized protocol for assessing engineered nanomaterials, but these concerns extend beyond traditional life cycle assessments in materials and reveal the need for a more holistic approach—including social impact assessment.